Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum β-lactamase

Rayo Morfín-Otero, Soraya Mendoza-Olazarán, Jesús Silva-Sánchez, Eduardo Rodríguez-Noriega, Jorge Laca-Díaz, Perla Tinoco-Carrillo, Luis Petersen, Perla López, Fernando Reyna-Flores, Dolores Alcantar-Curiel, Ulises Garza-Ramos, Elvira Garza-González

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The prevalence and genetic characteristics of Escherichia coli and Klebsiella pneumoniae clinical isolates producing extended-spectrum β-lactamase (ESBL) were examined. Between October 2010 and March 2011, E. coli (n=460) and K. pneumoniae (n=78) isolates were collected at a tertiary care hospital in Guadalajara, Mexico. The minimum inhibitory concentration (MIC) for each isolate was determined using a broth microdilution method, and ESBL production was assayed. The presence of β-lactamase genes, blaSHV, blaCTX-M, and blaTLA-1, was detected by PCR and confirmed with sequencing. Only ESBL-producing isolates were further subjected to pulsed-field gel electrophoresis (PFGE) and plasmid profiling. All of the ESBL isolates were multidrug resistant and 75/460 (16.3%) E. coli isolates and 21/78 (26.9%) K. pneumoniae isolates were found to produce ESBL. For the E. coli isolates, >95% susceptibility to amikacin, meropenem, fosfomycin, imipenem, and nitrofurantoin was observed. For K. pneumoniae, similar results were obtained, with discrepancies observed for gentamicin and nitrofurantoin. PFGE further identified eleven pulsotypes for E. coli and three clusters of K. pneumoniae. CTX-M-15 was detected in 85% of ESBL-producing E. coli and in 76% of ESBL-producing K. pneumoniae. In contrast, SHV-5 ESBL was identified in 17% of E. coli isolates and in 86% of K. pneumoniae isolates. The bla-TLA-1 gene was not detected in any of the 96 isolates analyzed. Overall, CTX-M-15 and SHV-5 were found to have a high rate of spread throughout the hospital and were associated with strong multidrug resistance.

Original languageEnglish
Pages (from-to)378-83
Number of pages6
JournalMicrobial Drug Resistance
Volume19
Issue number5
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Klebsiella pneumoniae
Enterobacteriaceae
Tertiary Healthcare
Mexico
Tertiary Care Centers
Escherichia coli
Nitrofurantoin
Pulsed Field Gel Electrophoresis
meropenem
Fosfomycin
Amikacin
Imipenem
Microbial Sensitivity Tests
Multiple Drug Resistance
Gentamicins
Genes
Plasmids
Polymerase Chain Reaction

Cite this

Morfín-Otero, Rayo ; Mendoza-Olazarán, Soraya ; Silva-Sánchez, Jesús ; Rodríguez-Noriega, Eduardo ; Laca-Díaz, Jorge ; Tinoco-Carrillo, Perla ; Petersen, Luis ; López, Perla ; Reyna-Flores, Fernando ; Alcantar-Curiel, Dolores ; Garza-Ramos, Ulises ; Garza-González, Elvira. / Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum β-lactamase. In: Microbial Drug Resistance. 2013 ; Vol. 19, No. 5. pp. 378-83.
@article{b2e1dc95a6a2468cb878a6771005dd98,
title = "Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum β-lactamase",
abstract = "The prevalence and genetic characteristics of Escherichia coli and Klebsiella pneumoniae clinical isolates producing extended-spectrum β-lactamase (ESBL) were examined. Between October 2010 and March 2011, E. coli (n=460) and K. pneumoniae (n=78) isolates were collected at a tertiary care hospital in Guadalajara, Mexico. The minimum inhibitory concentration (MIC) for each isolate was determined using a broth microdilution method, and ESBL production was assayed. The presence of β-lactamase genes, blaSHV, blaCTX-M, and blaTLA-1, was detected by PCR and confirmed with sequencing. Only ESBL-producing isolates were further subjected to pulsed-field gel electrophoresis (PFGE) and plasmid profiling. All of the ESBL isolates were multidrug resistant and 75/460 (16.3{\%}) E. coli isolates and 21/78 (26.9{\%}) K. pneumoniae isolates were found to produce ESBL. For the E. coli isolates, >95{\%} susceptibility to amikacin, meropenem, fosfomycin, imipenem, and nitrofurantoin was observed. For K. pneumoniae, similar results were obtained, with discrepancies observed for gentamicin and nitrofurantoin. PFGE further identified eleven pulsotypes for E. coli and three clusters of K. pneumoniae. CTX-M-15 was detected in 85{\%} of ESBL-producing E. coli and in 76{\%} of ESBL-producing K. pneumoniae. In contrast, SHV-5 ESBL was identified in 17{\%} of E. coli isolates and in 86{\%} of K. pneumoniae isolates. The bla-TLA-1 gene was not detected in any of the 96 isolates analyzed. Overall, CTX-M-15 and SHV-5 were found to have a high rate of spread throughout the hospital and were associated with strong multidrug resistance.",
author = "Rayo Morf{\'i}n-Otero and Soraya Mendoza-Olazar{\'a}n and Jes{\'u}s Silva-S{\'a}nchez and Eduardo Rodr{\'i}guez-Noriega and Jorge Laca-D{\'i}az and Perla Tinoco-Carrillo and Luis Petersen and Perla L{\'o}pez and Fernando Reyna-Flores and Dolores Alcantar-Curiel and Ulises Garza-Ramos and Elvira Garza-Gonz{\'a}lez",
year = "2013",
month = "10",
doi = "10.1089/mdr.2012.0263",
language = "English",
volume = "19",
pages = "378--83",
journal = "Microbial Drug Resistance",
issn = "1076-6294",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

Morfín-Otero, R, Mendoza-Olazarán, S, Silva-Sánchez, J, Rodríguez-Noriega, E, Laca-Díaz, J, Tinoco-Carrillo, P, Petersen, L, López, P, Reyna-Flores, F, Alcantar-Curiel, D, Garza-Ramos, U & Garza-González, E 2013, 'Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum β-lactamase', Microbial Drug Resistance, vol. 19, no. 5, pp. 378-83. https://doi.org/10.1089/mdr.2012.0263

Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum β-lactamase. / Morfín-Otero, Rayo; Mendoza-Olazarán, Soraya; Silva-Sánchez, Jesús; Rodríguez-Noriega, Eduardo; Laca-Díaz, Jorge; Tinoco-Carrillo, Perla; Petersen, Luis; López, Perla; Reyna-Flores, Fernando; Alcantar-Curiel, Dolores; Garza-Ramos, Ulises; Garza-González, Elvira.

In: Microbial Drug Resistance, Vol. 19, No. 5, 10.2013, p. 378-83.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum β-lactamase

AU - Morfín-Otero, Rayo

AU - Mendoza-Olazarán, Soraya

AU - Silva-Sánchez, Jesús

AU - Rodríguez-Noriega, Eduardo

AU - Laca-Díaz, Jorge

AU - Tinoco-Carrillo, Perla

AU - Petersen, Luis

AU - López, Perla

AU - Reyna-Flores, Fernando

AU - Alcantar-Curiel, Dolores

AU - Garza-Ramos, Ulises

AU - Garza-González, Elvira

PY - 2013/10

Y1 - 2013/10

N2 - The prevalence and genetic characteristics of Escherichia coli and Klebsiella pneumoniae clinical isolates producing extended-spectrum β-lactamase (ESBL) were examined. Between October 2010 and March 2011, E. coli (n=460) and K. pneumoniae (n=78) isolates were collected at a tertiary care hospital in Guadalajara, Mexico. The minimum inhibitory concentration (MIC) for each isolate was determined using a broth microdilution method, and ESBL production was assayed. The presence of β-lactamase genes, blaSHV, blaCTX-M, and blaTLA-1, was detected by PCR and confirmed with sequencing. Only ESBL-producing isolates were further subjected to pulsed-field gel electrophoresis (PFGE) and plasmid profiling. All of the ESBL isolates were multidrug resistant and 75/460 (16.3%) E. coli isolates and 21/78 (26.9%) K. pneumoniae isolates were found to produce ESBL. For the E. coli isolates, >95% susceptibility to amikacin, meropenem, fosfomycin, imipenem, and nitrofurantoin was observed. For K. pneumoniae, similar results were obtained, with discrepancies observed for gentamicin and nitrofurantoin. PFGE further identified eleven pulsotypes for E. coli and three clusters of K. pneumoniae. CTX-M-15 was detected in 85% of ESBL-producing E. coli and in 76% of ESBL-producing K. pneumoniae. In contrast, SHV-5 ESBL was identified in 17% of E. coli isolates and in 86% of K. pneumoniae isolates. The bla-TLA-1 gene was not detected in any of the 96 isolates analyzed. Overall, CTX-M-15 and SHV-5 were found to have a high rate of spread throughout the hospital and were associated with strong multidrug resistance.

AB - The prevalence and genetic characteristics of Escherichia coli and Klebsiella pneumoniae clinical isolates producing extended-spectrum β-lactamase (ESBL) were examined. Between October 2010 and March 2011, E. coli (n=460) and K. pneumoniae (n=78) isolates were collected at a tertiary care hospital in Guadalajara, Mexico. The minimum inhibitory concentration (MIC) for each isolate was determined using a broth microdilution method, and ESBL production was assayed. The presence of β-lactamase genes, blaSHV, blaCTX-M, and blaTLA-1, was detected by PCR and confirmed with sequencing. Only ESBL-producing isolates were further subjected to pulsed-field gel electrophoresis (PFGE) and plasmid profiling. All of the ESBL isolates were multidrug resistant and 75/460 (16.3%) E. coli isolates and 21/78 (26.9%) K. pneumoniae isolates were found to produce ESBL. For the E. coli isolates, >95% susceptibility to amikacin, meropenem, fosfomycin, imipenem, and nitrofurantoin was observed. For K. pneumoniae, similar results were obtained, with discrepancies observed for gentamicin and nitrofurantoin. PFGE further identified eleven pulsotypes for E. coli and three clusters of K. pneumoniae. CTX-M-15 was detected in 85% of ESBL-producing E. coli and in 76% of ESBL-producing K. pneumoniae. In contrast, SHV-5 ESBL was identified in 17% of E. coli isolates and in 86% of K. pneumoniae isolates. The bla-TLA-1 gene was not detected in any of the 96 isolates analyzed. Overall, CTX-M-15 and SHV-5 were found to have a high rate of spread throughout the hospital and were associated with strong multidrug resistance.

U2 - 10.1089/mdr.2012.0263

DO - 10.1089/mdr.2012.0263

M3 - Article

VL - 19

SP - 378

EP - 383

JO - Microbial Drug Resistance

JF - Microbial Drug Resistance

SN - 1076-6294

IS - 5

ER -